OS Therapies Provided an Update on Global Early Market Access Regulatory Coordination Efforts By UK's MHRA For OST-HER2 For Pulmonary Metastatic Osteosarcoma Under Project Orbis

OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health subsidiary,

OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment

OS Therapies reports a 72.7% three-year survival rate in its Phase 2b osteosarcoma trial, preparing for global regulatory submissions.

OS Therapies shares are trading high after the company announced it achieved a statistically significant final three-year overall survival benefit for OST-HER2-treated patients in its Phase 2b pulmonary metastatic osteosarcoma trial.

OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control

Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company